Activation of soluble epoxide hydrolase (sEH) is associated with endothelial dysfunction in hypertension, though the underlying mechanisms are inadequately understood and the role of endoplasmic reticulum (ER) stress is yet to be studied in detail. Tetramethylpyrazine (TMP), a major bioactive ingredient of Chinese herb Chuanxiong, is well-known for its cardiovascular benefits. Nevertheless, whether TMP may protect vascular endothelium from ER stress and whether regulation of sEH is involved remain unknown. This study aimed at investigating the role of ER stress in angiotensin-II (Ang-II)-induced sEH dysregulation and elucidating the significance of ER stress regulation in the vasoprotective effect of TMP. Porcine primary coronary artery endothelial cells (PCECs) were used for western blot, ELISA, and reverse-transcription PCR analysis. Porcine coronary arteries were assessed in a myograph for endothelial dilator function. Ang-II induced expression of ER stress molecules in PCECs meanwhile enhanced sEH expression and decreased 11,12-EET. Exposure of PCECs to the chemical ER stress inducer tunicamycin also increased sEH expression. Inhibition of ER stress suppressed sEH upregulation, resulting in an increase of 11,12-EET. The impairment of endothelium-dependent vasorelaxation induced by Ang-II or tunicamycin was ameliorated by inhibitors of ER stress or sEH. TMP showed comparable inhibitory effect to ER stress inhibitors on the expression of ER stress molecules, the dysregulation of sEH/EET, and the impairment of endothelial dilator function. We demonstrated that ER stress mediates Ang-II-induced sEH upregulation in coronary endothelium. TMP has potent anti-ER stress capacity through which TMP normalizes sEH expression and confers protective effect against Ang-II on endothelial function of coronary arteries.
Introduction
Epoxy fatty acids (EpFAs), such as epoxyeicosatrienoic acids (EETs) derived from arachidonic acid, are important lipid mediators that have pathophysiological significance in the cardiovascular system (Arnold et al., 2010) . EETs are potent vasodilators that possess properties of endothelium-derived hyperpolarizing factor (EDHF) (Campbell et al., 1996) . Through inhibiting inflammation and platelet aggregation, EETs help maintain vascular homeostasis (Larsen et al., 2007) . Soluble epoxide hydrolase (sEH) rapidly hydrolyses EpFAs to less bioactive diols, for example, EETs to DHETs, thereby is critical in controlling the bioavailability of EETs and other EpFAs . sEH activation and associated endothelial dysfunction have been implicated in the pathogenesis of various cardiovascular diseases including hypertension, atherosclerosis, and metabolic disorders . However, knowledge of the mechanisms by which sEH is activated in these diseased conditions so far remains inadequate.
Endoplasmic reticulum (ER) stress is involved in endothelial dysfunction in hypertension and recent studies revealed ER stress-induced eNOS-NO inhibition (Kassan et al., 2012) as an underlying mechanism that involves decrease of eNOS phosphorylation and increase of oxidative stress. Hypertension-associated endothelial dysfunction is also related to ER stress-mediated increase of endothelium-derived contracting factors (Spitler et al., 2013) . Nevertheless, whether ER stress dysregulates endothelial sEH to contribute to vascular pathology in http://dx.doi.org/10.1016/j.taap.2017.10.016 Received 14 July 2017; Received in revised form 15 September 2017; Accepted 18 October 2017 hypertension is yet to be explored.
Tetramethylpyrazine (TMP), an alkaloid that being a major active ingredient of Chinese herb Chuanxiong (rhizoma Ligustici wallichii), is well-known for its cardiovascular benefits. TMP is also detected in natto (Kosuge et al., 1962) , a traditional Japanese fermented food that has powerful protective effect on heart and circulatory system. Attributable to its strong antioxidant and anti-inflammatory properties, TMP protects endothelial function via enhancing Akt/eNOS phosphorylation, alleviating oxidative stress with enhanced activity of antioxidants, e.g. SOD, and/or decreased activity of oxidants, e.g., NADPH oxidase, and suppressing expression of pro-inflammatory mediators in endothelial cells (Jiang et al., 2011; Lv et al., 2012; Wang et al., 2013; Ni et al., 2014) . Despite progress in understanding the vasoprotective mechanism of TMP, much remains to be studied. For example, whether TMP possesses anti-ER stress properties to confer vasoprotection and whether regulation of endothelial sEH is involved are barely known. In the light of accumulating evidence implicating ER stress in inflammatory and other diseases (Chaudhari et al., 2014; Mahdi et al., 2016) , and recent findings of the blocking effect of EpFAs on ER stress (Inceoglu et al., 2012; Inceoglu et al., 2017) , studies concerning the effect of TMP on ER stress and sEH and the linkage between may further our understanding of spectrum of effects of TMP, which may ultimately broaden the therapeutic potential and clinical application of this compound.
The present study therefore aimed to investigate whether ER stress is involved in angiotensin II (Ang-II)-induced sEH dysregulation in coronary endothelium and whether anti-ER stress mechanism is involved in the endothelial protective effect of TMP through regulation of sEH.
Materials and methods

Reagents and materials
Angiotensin-II (Ang-II) and U46619 were purchased from Cayman Chemical (Michigan, USA). 12- [[(tricyclo[3.3.1.13,7] dec-1ylamino) carbonyl]amino]dodecanoic acid (AUDA), bradykinin, tunicamycin, tetramethylpyrazine (TMP), tauroursodeoxycholic acid (TUDCA), 4-phenylbutyric acid (4-PBA), and triphenylphosphine were purchased from Sigma-Aldrich Inc. (Darmstadt, Germany). Roswell Park Memorial Institute medium (RPMI-1640), fetal bovine serum (FBS), and medium 131 were purchased from Thermal Fisher Scientific Inc. (Waltham, USA).
Preparation of porcine coronary arteries
Fresh hearts of young adult pigs (~35 kg) were collected from a local slaughterhouse. Once the pig was slaughtered the heart was placed in cold (4°C) and pre-oxygenated Krebs solution, which is composed of (in mmol/L): 118 NaCl, 4.7 KCl, 25.2 NaHCO 3 , 2.5 CaCl 2 , 1 MgSO 4 (7H 2 O), 1.2 KH 2 PO 4 , and 11.1 D-glucose, and immediately transferred to laboratory for experimentation. All experiments were in accordance with institutional guidelines and approved by the Animal Experimentation Ethics Committee, and Safety Office of the Chinese University of Hong Kong. Main truck and branches of the left anterior descending artery (LAD) were excised and cleared of the adherent connective tissues. The arteries were further used for primary cell culture or subjected to vasoreactivity study as appropriate. Fig. 1 . Ang-II induces ER stress in PCECs. Exposure to Ang-II for 24 h significantly increased the expression of GRP78 and ATF6, and enhanced the phosphorylation of PERK and IRE1, which was prevented by ER stress inhibitors either TUDCA or 4-PBA. The level of phosphorylated PERK (p-PERK) or IRE1 (p-IRE1) was normalized to total PERK (PERK) or IRE1 (IRE1) protein level in the same sample. Expression of ATF6 or GRP78 was normalized to β-actin. n = 6 in each group. ⁎⁎ p < 0.01 vs control (CTL), ## p < 0.01 vs Ang-II.
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Coronary endothelial cells (PCECs) were isolated by enzymatic digestion from porcine coronary arteries and cultured as previously described Yang et al., 2011; Yang et al., 2014; Wang et al., 2015) . Briefly, coronary arteries were dissected into small strips and treated with 0.2% collagenase (type I, Sigma) at 37°C for 25 min. The suspension was then centrifuged at 1600 rpm for 5 min and cells were resuspended in 5 mL culture medium containing 90% RPMI, 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin. After 2 h incubation at 37°C, the medium was replaced once to remove unattached cells. Attached cells were further grown in Medium 131 containing 5% microvascular growth supplement, 100 U/mL penicillin, and 100 μg/ mL streptomycin, in a humidified incubator with 5%CO 2 at 37°C for 6 days. The medium was changed every 2 to 3 days.
Assessment of endothelial dilator function
Segments of small branches of LAD (2 mm in length) were mounted in a DMT wire myograph (model 610A; J.P. trading, Aarhus, Denmark) and aerated in Krebs continuously with 95%O 2 and 5%CO 2 at 37 ± 0.1°C. The vessel rings were equilibrated for 45 min before normalization, whereby they were set at the internal circumference equivalent to 90% of the circumference at a passive transmural pressure of 100 mmHg (He et al., 1989; Yang et al., 2002) . The vessels were then equilibrated for 45 min prior to pre-constriction with U46619. Preconstriction was allowed to reach plateau before the endothelium-dependent vasorelaxation was assessed by cumulative application of bradykinin (− 10~−6.5 logM).
Western blot assay
Whole cell protein was extracted from primary PCECs with lysis buffer containing protease and phosphatase inhibitor cocktail (Roche Diagnostics). Protein concentration was determined by bicinchoninic acid assay. The protein was aliquoted with 6X loading buffer (100 mmol/L pH 6.8 Tris-HCl, 4% SDS, 20% Glycerol, 10% 2-mercaptoenthanol, 0.25% bromophenol blue) and 35 μg of protein was loaded and separated on 8% gel of sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) at 100 V for 2 h. The fractionated proteins were then transferred to activated immobilon-P polyvinylidene difluoride (PVDF) membrane using wet transfer at 100 V for 90 min at 4°C. Non-specific binding was blocked with 5% BSA in 0.01% Tween-20 Tris-buffered saline (TBST) for 1 h under room temperature, with gentle agitation applied. The proteins were then probed overnight at 4°C in 0.01% TBST containing 1% BSA with primary antibodies against target molecules, including sEH (1:500, Cayman chemical Co., USA) and ER stress-related molecules 78-kDa glucose-regulated protein (GRP78) (1:1000, Abcam, USA), activating transcription factor 6 (ATF6) (1:500, Abnova, Taiwan), protein kinase RNA-like endoplasmic reticulum kinase (PERK) [phorsphorylated (Thr980) and total: p-PERK (1:500, Bioss, USA), PERK (1:500, Cell signaling, USA)], and inositolrequiring enzyme 1 (IRE1) [phorsphorylated (Ser724) and total: p-IRE1 (1:500, Abcam, USA), IRE1 (1:500, Abcam, USA)]. β-actin (1:4000, Abcam, USA) was used as loading control. After multiple washes with TBST, the membranes were incubated with HRP-conjugated goat antirabbit IgG or anti-mouse IgG secondary antibodies (1: 10,000) for 1 h at room temperature in darkness under gentle agitation. The blots were washed with TBST to remove the unconjugated antibodies. Imaging was Fig. 2 . TMP inhibits Ang-II-induced ER stress in PCECs. TMP was studied in four different concentrations: 1 μmol/L (TMP1), 10 μmol/L (TMP10), 100 μmol/L (TMP100), and 1000 μmol/L (TMP1000). At concentrations ≥ 100 μmol/L TMP significantly inhibited Ang-II-induced upregulation of ER stress molecules. Protein expression of GRP78 or ATF6 was normalized to β-actin, and phosphorylated PERK (p-PERK) or IRE1 (p-IRE1) was normalized to total PERK (PERK) or IRE1 (IRE1) in the same sample. n = 7 in each group. S.-K. Mak et al. Toxicology and Applied Pharmacology 336 (2017) 84-93 performed at a wavelength of 800 nm by using Li-Cor Odyssey InfraRed gel imaging scanner (Li-Cor Biosciences). The intensity of the bands was analyzed by Quantity One imaging system (Version 4.6.6, Bio-Rad).
Reverse transcription polymerase chain reaction (RT-PCR)
RNA was extracted using TRIzol reagent (Invitrogen) according to the manufacturer's instruction. cDNA was synthesized using reverse transcriptase kit (PrimeScript™ RT Master Mix, TaKaRa Biotechnology, China). PCR amplification was performed using GoTaq® G2 Flexi DNA Polymerase (Promega, USA) in Heal Force Thermal Cyclers Genemate T960 Touch (Hong Kong). Amplification parameters were set as follows: 95°C activation (30 s) followed by 95°C dissociation (30 s), 72°C annealing (1 min), and 72°C elongation (5 min), for 30 cycles. Primers used for PCR amplification have the sequence of: sEH, 5'-TGGATGATGTCGGGACT-3' (sense) and 5'-TATTTCGGGAGGAGCAG-3' (anti-sense); GAPDH, 5'-TGTACCACCAACTGCTTGGC-3' (sense) and 5'-GGCATGGACTGTGGTCATGAG-3' (anti-sense). PCR products were fractionated by gel electrophoresis, and visualized and digitally imaged by UV transilluminator Gel Doc™ EZ Imager (Bio-Rad). Density analysis of the signals was evaluated using the GelQuant.NET 1.8.2 software (Biochemlabsolutions, University of California, San Francisco). Data were normalized by GAPDH for analysis.
Enzyme-linked immunosorbent assay (ELISA) of 11,12-EET
PCECs were collected and sonicated in PBS containing 0.1 mmol/L of triphenylphosphine (0.03-0.05 mg/mL), followed by acidification with acetic acid to pH 3-4. Ethyl acetate was then used to extract the cell lysates. The organic phase was collected and evaporated before reconstituted with 100% ethanol for ELISA. 11,12-EET production was detected by a commercialized 11,12-EET/DHET ELISA kit (Detroit R & D) according to the manufacturer's instructions. In brief, 11,12-DHET stock standards (10 pg/mL to 1,000,000 pg/mL) were used to construct a standard curve. Samples and 11,12-DHET-HRP conjugate were added to a 96-well culture plate pre-coated with 11,12 DHET antibody, where 11,12 DHET in the sample competes with the added 11,12 DHET-HRP for antibody binding. The plate was incubated for 2 h at room temperature before being washed and dried. Tetramethylbenzadine was added to react with HRP to form the blue color after 30-min incubation at room temperature. Sulfuric acid (2 N) was added to stop the reaction, and the plate was read at 450 nm using EnSpire® Multimode Reader (Perkin Elmer, USA).
Statistical analysis
Relaxation was expressed as the percentage decrease of pre-contraction induced by U46619. Data were presented as mean ± SEM. Statistical analyses were performed by one-way ANOVA followed by Scheffe tests (SPSS, version 20). p < 0.05 was considered statistically Fig. 3 . TMP inhibits ER stress in tunicamycin-exposed PCECs with a similar capacity as the ER stress inhibitors. TMP (100 μmol/L) and ER stress inhibitors, i.e., TUDCA and 4-PBA showed similar inhibitory effect on tunicamycininduced upregulation of ER stress molecules. Protein expression of GRP78 or ATF6 was normalized to β-actin, and phosphorylated PERK (p-PERK) or IRE1 (p-IRE1) was normalized to total PERK (PERK) or IRE1 (IRE1) in the same sample. n = 7 in each group. ⁎⁎ p < 0.01 vs control (CTL), ## p < 0.01 vs tunicamycin (TM).
S.-K. Mak et al. Toxicology and Applied Pharmacology 336 (2017) 84-93 significant.
Results
Ang-II induces ER stress in PCECs and TMP exhibits anti-ER stress effect
We first examined the effect of Ang-II on the ER of PCECs. PCECs were treated with Ang-II (100 nmol/L) for 24 h in the presence or absence of ER stress inhibitors either tauroursodeoxycholic acid (TUDCA, 200 μmol/L) or 4-phenylbutyric acid (4-PBA, 2 mmol/L). TUDCA or 4-PBA was applied 1 h prior to administration of Ang-II. Western blot analysis showed that compared to the control cells without Ang-II exposure, the expression of ER stress markers, i.e., GRP78, ATF6, p-PERK, and p-IRE1, were significantly upregulated in Ang-II exposed PCECs, which was prevented by TUDCA or 4-PBA treatment, suggesting the induction of ER stress by Ang-II in the endothelium of coronary arteries (Fig.1) .
Next, we studied whether TMP may protect PCECs from ER stress. Ang-II-exposed PCECs were co-incubated with various concentrations of TMP (1, 10, 100, and 1000 μmol/L), which was applied 1 h prior to Ang-II. TMP was observed to effectively inhibit Ang-II-induced ER stress in PCECs. At concentrations ≥100 μmol/L, TMP significantly downregulated Ang-II-induced protein expression of GRP78, ATF6, p-PERK, and p-IRE1 (Fig.2) . Further studies with tunicamycin, a chemical ER stress inducer, provided additional proof in support of the anti-ER stress activity of TMP. In PCECs subjected to tunicamycin exposure, cotreatment with 100 μmol/L TMP significantly suppressed the increase of GRP78 and ATF6 proteins and the enhancement of PERK and IRE1 phosphorylation, and the effect was comparable to that of ER stress inhibitors TUDCA and 4-PBA (Fig.3) .
In PCECs without Ang-II or tunicamycin exposure, TMP or ER stress inhibitor itself did not affect the expression of ER stress-related molecules ( Supplementary Fig. 1 ). Cell viability tests showed no differences among the control group and the groups exposed to Ang-II, tunicamycin, or Ang-II in conjunction with different doses of TMP (all > 93%).
sEH expression is upregulated in ER-stressed PCECs
To study whether ER stress is involved in the regulation of sEH, PCECs were treated with Ang-II (24 h) or tunicamycin (6 h) in the presence or absence of the ER stress inhibitor TUDCA. Ang-II-exposed PCECs exhibited significant upregulation in the expression of sEH at both the mRNA and the protein level. Such upregulation was prevented by inhibition of ER stress with TUDCA (Fig. 4a) . The suppressing effect of TUDCA on sEH upregulation was also observed in PCECs subjected to tunicamycin exposure. Compared with tunicamycin-exposed cells, both the mRNA and the protein level of sEH were significantly lower in cells co-treated with tunicamycin and TUDCA, which did not differ from the control group (Fig. 4b) . S.-K. Mak et al. Toxicology and Applied Pharmacology 336 (2017) 84-93 3.3. TMP shows comparable effect as ER stress inhibitors in normalizing sEH expression in ER-stressed PCECs TMP at 100 μmol/L suppressed sEH upregulation in ER-stressed PCECs. Both the mRNA and the protein level of sEH were significantly lowered by TMP in Ang-II-exposed cells. Likewise, PCECs co-treated with TMP and tunicamycin showed marked inhibition in mRNA and protein expressions of sEH, in comparison to the cells treated with tunicamycin alone. The inhibitory effect of TMP on sEH upregulation was comparable to that of the ER stress inhibitor TUDCA under both Ang-II and tunicamycin-exposed conditions (Fig.5a & b) .
TMP and ER stress inhibitor show comparable efficacy in preserving EET content in Ang-II-exposed PCECs
Prevention of ER stress-induced sEH upregulation conferred by TMP consequently leads to preservation of EET levels in Ang-II exposed PCECs. PCECs subjected to Ang-II exposure showed a significant elevation in 11,12-DHET concentration, indicating a decrease in 11,12-EET content. Treatment of the cells with TMP or the ER stress inhibitor TUDCA significantly increased the level of 11,12-EET, reflected by a lowered concentration of 11,12-DHET. TMP and TUDCA yielded similar efficacy in preserving 11,12-EET content in PCECs under Ang-II exposure condition (Fig. 6) . Fig. 5 . TMP inhibits the upregulation of sEH expression in ER-stressed PCECs with a similar capacity as the ER stress inhibitors. In PCECs exposed to Ang-II (a) or tunicamycin (TM) (b), TMP (100 μmol/L) and the ER stress inhibitor TUDCA showed similar inhibitory effect on the expression of sEH at both the mRNA (left panel of a & b) and the protein (right panel of a & b) level. n = 9 in each group. ⁎⁎ p < 0.01 vs control (CTL), ## p < 0.01 vs Ang-II or TM. Fig. 6 . TMP suppresses Ang-II-induced elevation of 11,12-DHET level in PCECs and the effect is comparable to that of the ER stress inhibitor TUDCA. Elevation/reduction of 11,12-DHET concentration indirectly reflects reduction/elevation of 11,12-EET level. n = 7 in each group. All samples were analyzed in duplicate wells and results were calculated from the means of duplicate sample analysis. 
ER stress-mediated upregulation of sEH contributes to Ang-II-induced endothelial dysfunction in coronary arteries
Exposure to Ang-II for 24 h significantly attenuated bradykinin-induced endothelium-dependent relaxation (55.4 ± 3.0% vs 92.9 ± 1.1% in the control, p < 0.01) in coronary arteries and treatment of the arteries with the ER stress inhibitor TUDCA ameliorated Ang-II-induced impairment (81.6 ± 4.8%, p < 0.01). Coronary arteries subjected to tunicamycin exposure also showed compromised endothelium-dependent relaxation. The maximal response declined from 93.7 ± 1.3% to 54.6 ± 2.6% (p < 0.01), which was restored by TUDCA (85.9 ± 1.1%, p < 0.01). These results indicate the detrimental effect of ER stress on endothelial dilator function and suggest that ER stress is a mechanism contributing to Ang-II-induced endothelial dysfunction (Fig. 7a & b) .
In arteries subjected to Ang-II or tunicamycin exposure, treatment with the sEH inhibitor AUDA was able to improve endothelial dilator function. Bradykinin-induced relaxation was restored from 54.9 ± 3.1% to 76.4 ± 2.3% (p < 0.01) in Ang-II-exposed arteries, and from 53.9 ± 2.5% to 67.6 ± 2.9% (p < 0.05) in tunicamycinexposed ones. In conjunction with the above results of sEH and EET determination, these data support the role of ER stress-mediated sEH dysregulation in Ang-II-induced impairment of endothelial dilator function (Fig.7c & d) .
3.6. Anti-ER stress mechanism is involved in the protective effect of TMP on endothelial dilator function TMP showed protective effect against Ang-II and tunicamycin on endothelial dilator function. The maximal relaxant response to bradykinin was restored by TMP in Ang-II-exposed arteries from 54.1 ± 4.2% to 87.7 ± 2.5% (p < 0.01) and from 51.5 ± 2.9% to 81.0 ± 3.6% in tunicamycin-exposure (p < 0.01). Moreover, TMP was similarly efficient as the ER stress inhibitor in restoring endothelium-dependent relaxation in both Ang-II-and tunicamycin-exposure (Fig.7e & f) .
For vessel studies, treatment protocols were the same as those for cell studies, i.e., Ang-II exposure for 24 h and tunicamycin exposure for 6 h, with ER stress inhibitors, sEH inhibitor, or TMP applied 1 h before and lasted for the whole exposure period. Fig. 7 . Inhibition of ER stress protects endothelial dilator function of coronary arteries from Ang-II (a) and tunicamycin (TM) (b) -induced impairment. Improvement of endothelial dilator function was also achieved by inhibition of sEH during exposure to Ang-II (c) and TM (d). TMP protects endothelial dilator function from Ang-II (e) and TM (f) -induced impairment. TMP was applied at a concentration of 100 μmol/L. The endothelium-dependent relaxation of coronary arteries was assessed by bradykinin in U46619-preconstriction. n = 8 in each group. S.-K. Mak et al. Toxicology and Applied Pharmacology 336 (2017) 84-93 
Discussion
The present study demonstrated that 1) ER stress mediates Ang-IIinduced sEH upregulation in coronary endothelium, and 2) TMP has potent anti-ER stress capacity through which TMP normalizes sEH expression thereby EET content and confers protective effect against Ang-II on endothelial function of coronary arteries.
The essential role of Ang-II in the development and progression of hypertension has been well documented (Pool, 2000) . Being more than merely a potent vasoconstrictor, Ang-II was extensively reported for its capacity of promoting ROS production and inhibiting eNOS-NO function (Nakashima et al., 2006) , with interplay in mediating endothelial dysfunction and vascular injury. The disruption caused by Ang-II of the vasodilator function also involves enhanced production of contracting factors such as endothelin-1 (Hsu et al., 2004 ) and alteration of EDHFtype dilatory response (Dal-Ros et al., 2009) . In this study, we observed that treatment of coronary arteries with the sEH inhibitor AUDA protects endothelial dilator function from Ang-II-induced impairment. AUDA, besides its potent inhibitory effect on sEH, was reported to act directly on vascular smooth muscle to induce dilation of mesenteric arteries as a mimic of EETs though this occurs at concentrations higher than sEH inhibition (Olearczyk et al., 2006) . In our study, coronary arteries were pretreated with AUDA and the relaxant response to bradykinin was assessed after repeated washout, which ruled out the direct vasodilatory action of this compound. Results yielded from cell studies showed a significant upregulation of sEH expression in Ang-II exposed PCECs at both the protein and the mRNA level. These results are consistent with the findings of previous studies, for example, Ang-II induced upregulation of sEH in human umbilical vein and bovine aortic endothelial cells (Ai et al., 2007) , and inhibition of sEH restored endothelium-dependent relaxation in hypertensive rats infused with Ang-II (Imig et al., 2002; Zhang et al., 2011) . Considering that Ang-II is an inflammatory agent and increase of sEH level is observed in inflammatory process in many tissues, the upregulation of sEH by Ang-II thereby may imply significance of this mechanism in various inflammatory diseases including but not limited to hypertension.
Given that sEH is a key enzyme controlling the level of EETs and EETs is a candidate for EDHF, we believed that loss of EETs resulting from sEH upregulation is a molecular explanation to the phenomenon of Ang-II-induced attenuation of dilatation in porcine coronary arteries. Further measurement with ELISA indeed confirmed the decrease of EETs level in Ang-II-exposed PCECs.
Importantly, our study added one piece of new information into the mechanistic understanding of EETs loss in hypertension with the finding of ER stress-mediated sEH upregulation. We observed that inhibition of ER stress during Ang-II exposure prevents the upregulation of sEH mRNA and protein expressions in PCECs, along with a significant elevation of 11,12-EET level. The induction of sEH expression by tunicamycin, a chemical ER stress inducer, provided parallel evidence supporting the role of ER stress in the regulation of sEH in coronary endothelium.
It is noteworthy to mention that recent studies reported the protective effect of EETs against cellular ER stress. Treatment with exogenous EETs was proven to suppress ER stress caused by cigarette smoke extracts and inhibit cell apoptosis in human bronchial epithelial cell line , alleviate ER stress in cardiomyocytes, and protect against cardiac failure in mice You et al., 2016) . In animals fed with high-fat diet, it was observed that sEH deficiency/inhibition significantly attenuates ER stress in liver and adipose tissue (Bettaieb et al., 2013) . The findings of the causative role of ER stress in modulation of pain signaling (Inceoglu et al., 2015) and the alleviation of neuropathic pain achieved by stabilization of EpFAs in diabetic animals using sEH inhibitors (Inceoglu et al., 2012 ) also supported the concept that EpFAs possess anti-ER stress properties. These results demonstrated that EpFAs such as EETs is a physiological modulator of ER stress in various cell types, which may also apply to vascular endothelial cells. Consequently, it is reasonable to hypothesize that in PCECs subjected to Ang-II exposure, decrease of EETs caused by ER stress may further deteriorate ER stress. In other words, we assume that sEH upregulation and ER stress might compose a positive feedback loop contributing to vascular pathology in hypertension. Given the significance of sEH upregulation in inflammation and the coupling of ER stress and inflammatory response (Zhang and Kaufman, 2008) , the speculation of positive feedback between sEH upregulation and ER stress may be generally true for diseases involving inflammation. Further research is warranted to confirm this.
A primary novel finding from the present study is that TMP has anti-ER stress activity and through this capacity TMP inhibits Ang-II-induced sEH upregulation thereby confers protective effect against Ang-II on endothelial function of coronary arteries.
The potent anti-ER stress capacity of TMP was demonstrated in PCECs whose ER was stressed by tunicamycin or Ang-II. TMP exhibited similar efficiency as the classical ER stress inhibitor TUDCA or 4-PBA in suppressing the expression of ER stress markers, i.e., GRP78, ATF6, p-PERK, and p-IRE1. Meanwhile, in either tunicamycin or Ang-II-exposed PCECs, TMP suppressed sEH expression at both the mRNA and the protein level. Comparison between TMP and the ER stress inhibitor showed similar effect of these compounds in normalizing sEH expression and preserving 11,12-EET level in ER-stressed PCECs. At tissue level, the prevention of sEH/EETs dysregulation by TMP against ER stress manifested as an improved endothelium-dependent vasorelaxation. Taken together, these data suggest that through inhibition of ER stress, TMP normalizes sEH expression hence preserves EETs level to confer protection against Ang-II on endothelial dilator function. Being supported by these findings, we may further speculate that ER stress inhibitors/chemical chaperones and synthetic mimics of EETs or other EpFAs as well as sEH inhibitors could be used to treat a wide variety of disorders by reducing underlying ER stress and inflammation.
Considering that EETs are not only an EDHF-type vasodilator but also have anti-inflammatory and anti-oxidant activity (Larsen et al., 2007) , we believe that the anti-ER stress-conferred preservation of EETs very likely contributes to the anti-inflammatory and anti-oxidant effects of TMP, though this needs to be examined in future investigations. In addition, although the blocking effect of EETs on ER stress in PCECs was not evaluated in this study, findings regarding EpFAs in particular EETs as inhibitors of ER stress have been reported in various cell types such as lung epithelium, cardiomyocyte, neurons, and adipocytes, and this mechanism has been proved to significantly contribute to the renal and cardiovascular protective effect and the antihyperalgesic effect of EpFAs (Khan et al., 2013; Xu et al., 2013; Wang et al., 2014; Inceoglu et al., 2015; Yu et al., 2015) . Nevertheless, current available evidence is insufficient to answer the question whether EpFAs blocks ER stress that leads to suppression of inflammatory response or EpFAs blocks inflammation that subsequently reduces ER stress. Further studies on this shall provide more comprehensive understanding of the molecular basis of the therapeutic effect of EETs and other EpFAs.
Limitations of the study
While the present study unraveled the role of ER stress in Ang-IIinduced sEH/EETs dysregulation and the significance of anti-ER stress mechanism in the vasoprotection conferred by TMP, this study made no further attempt to explore the significance of the individual ER stress sensors, i.e., PERK, IRE1, and ATF6. Further revealing the intracellular signaling driven by ER stress sensing is warranted to provide a more profound understanding of the role played by ER stress and the protection conferred by TMP in the regulation of sEH/EETs. Another closely-related question that this study did not provide answers for is whether cytochrome P450 (CYP) epoxygenases in particular CYP2C and CYP2J contribute to the ER stress-mediated loss of EETs in Ang-II exposed PCECs, studies regarding the effect of TMP on CYP epoxygenases with focus on the anti-ER stress mechanism would be a direction for future research. It has emerged that ER stress and oxidative stress interconnects in progression of inflammation, with mitochondria being both the source and the target of ROS (Chaudhari et al., 2014) . Moreover, accumulating evidence suggests that EpFAs and sEH inhibitors may stabilize the mitochondria to reduce intracellular ROS formation and to block ER stress (Inceoglu et al., 2017) . Based on our finding of the anti-ER stress-dependent normalization of sEH/EET by TMP, it would be very interesting to further study the regulatory effect of TMP on the signaling loop connecting mitochondria, ROS, and ER. In addition, the present study was an in vitro investigation. Although use of cell culture and isolated vessels has been widely employed in mechanistic studies of vascular endothelial function, future in vivo studies shall help further evaluate the in vitro findings, and extra caution should be taken when extrapolating results from this experimental investigation to clinical settings.
Potential implications
By revealing ER stress-mediated regulation of sEH in coronary endothelial cells, the present study added new knowledge to the mechanisms of Ang-II-induced endothelial dysfunction and extended our understanding of the role played by ER stress in hypertension pathology. Results derived from this study provided a basis for future investigations on signaling cascades involved in ER stress-mediated regulation of sEH, which may help identify new potential target sites for treating hypertension and other types of cardiovascular disease. The finding of anti-ER stress capacity of TMP provided new mechanistic insight into the cardiovascular benefits of this traditional Chinese medicine. The results regarding the effectiveness of TMP and other molecular chaperones in suppressing ER stress and preserving EETs bioavailability/function may support broadening the use of these compounds in the treatment of diseases whose pathogenesis involves ER stress.
In summary, we demonstrated that ER stress mediates Ang-II-induced sEH upregulation in coronary endothelial cells. TMP suppresses Ang-II-induced upregulation of sEH, which can be attributed to its anti-ER stress capacity. These findings added new mechanistic insight into the cardiovascular benefits of this traditional Chinese medicine that may have potential clinical implications.
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